Imgenex Corp. develops and commercializes novel reagents for the scientific study of human biology and disease and for the production of new diagnostic assays and potential therapies of such diseases. These novel reagents include antibodies, gene and protein expression systems, and arrays of various cells and tissues for use in studies of functional genomics. Areas of biological interest at IMGENEX include cancer, apoptosis (programmed cell death), molecular signaling pathways, cellular aging, and metabolic and infectious diseases.

TRADD (TNF Receptor Associated Death Domain) is a 36kD protein that interacts specifically with the cytoplasmic domain of the type I TNF Receptor. TRADD has been shown to interact with TRAF1, TRAF2, and FADD to allow recruitment of these molecules to the TNF receptor complex.